Cure My Disease

Don't miss your cure!

 Log in / Sign up

New combo therapy aims to beat tough childhood lymphoma

NCT ID NCT07013565

Recruiting now Disease control Sponsor: New York Medical College Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial tests a risk-adapted treatment for children, adolescents, and young adults with relapsed or refractory ALK-positive anaplastic large cell lymphoma. Participants receive nivolumab (an immunotherapy) combined with chemotherapy drugs like vinblastine or brentuximab vedotin, followed by a stem cell transplant from a donor. The goal is to improve survival and reduce side effects by tailoring treatment to each patient's risk level.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Nivolumab (immunotherapy), vinblastine (chemotherapy), and brentuximab vedotin (targeted drug)
What this could lead to
If successful, this could improve survival rates for children and young adults with hard-to-treat ALK+ anaplastic large cell lymphoma.
What could go wrong
This is a small, early-phase trial with only 20 participants, so results may not apply to everyone. The treatment includes strong chemotherapy and stem cell transplant, which carry serious risks like infection and organ damage.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ANAPLASTIC LARGE CELL LYMPHOMA, ALK-POSITIVE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

ALK-positive anaplastic large cell lymphoma anaplastic large cell lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ANAPLASTIC LARGE CELL LYMPHOMA, ALK-POSITIVE

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • New York Medical College

    RECRUITING

    Valhalla, New York, 10595, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.